Contents

Search

Kras gene mutation analysis

Indications: - defects in KRAS are a cause of a) acute myelogenous leukemia b) juvenile myelomonocytic leukemia c) Noonan syndrome 3 d) cardiofaciocutaneous syndrome e) KRAS mutations are involved in cancer development, colorectal carcinoma [4] f) lung cancer [4] g) pancreatic cancer [4] Pharmacology: - mutations in Kras associated with lack of effectiveness of a) cetuximab (Erbitux) b) panitumumab (Vectibix) Laboratory: - LOINC: 21702-6, 21704-4, 53620-1

Related

K-ras 2 proto-oncogene

Specific

KRAS gene mutation in colorectal cancer

General

gene mutation testing; gene mutation analysis

References

  1. Lievre A et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008 Jan 20; 26:374. PMID: 18202412
  2. Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep. 2010 May;12(3):160-7. PMID: 20425075 - Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010 Mar;32(3):437-53. PMID: 20399983
  3. KRAS Mutation Detection Laboratory Test Directory ARUP: 40248
  4. Sumnners C What's new in KRAS mutation research? MD Anderson 2024. April 4 https://www.mdanderson.org/cancerwise/what-s-new-in-kras-mutation-research-.h00-159696756.html

Component-of

Kras + Nras gene mutation